ABSTRACT
Tc-MEB and 99m Tc-MIBI disposition was determined in suspended hepatocytes and in SCH in the presence and absence of inhibitors and genetic knockdown of breast cancer resistance protein (Bcrp). Results The general organic anion transporting polypeptide (Oatp/OATP) inhibitor rifamycin SV reduced initial 99m Tc-MEB uptake in rat and human suspended hepatocytes. Initial 99m Tc-MIBI uptake in suspended rat hepatocytes was not Na + -dependent or influenced by inhibitors. Multidrug resistance-associated protein (Mrp2/MRP2) inhibitors decreased 99m Tc-MEB canalicular efflux in rat and human SCH. Tc-MEB efflux in human SCH was predominantly canalicular (45.8±8.6%) and ∼3-fold greater than in rat SCH. Tc-MIBI canalicular efflux was similar in human and rat SCH; basolateral efflux was 37% greater in human than rat SCH. Tc-MIBI cellular accumulation, biliary excretion index and in vitro biliary clearance in rat SCH were unaffected by Bcrp knockdown. Conclusion 99m Tc-MEB hepatic uptake is predominantly Oatp-mediated with biliary excretion by Mrp2. 99m Tc-MIBI appears to passively diffuse into hepatocytes; biliary excretion is mediated by P-gp. The SCH model is useful to investigate factors that may alter the route and/or extent of hepatic basolateral and canalicular efflux of substrates. 99m Technetium-sestamibi ( 99m Tc-MIBI) are candidate probe substrates for multidrug resistance-associated protein 2 (MRP2) and P-gp, respectively.
KEY WORDS
99m Tc-MEB is the 99m Tc-labeled trimethylbromo analogue of acetanilidoiminodiacetic acid commonly used in nuclear medicine for hepatobiliary scintigraphy and evaluation of gallbladder dysfunction (1) . This compound belongs to a class of agents that couples a lidocaine-like structure, resulting in high liver extraction, with 99m technetium, which is ideal for gamma scintigraphy (2) . Several hepatic transport proteins involved in the hepatobiliary disposition of 99m Tc-MEB were characterized recently in expressed systems including OATP1B1, OATP1B3, MRP2 and MRP3 (3). 99m Tc-MEB exhibited increased and prolonged hepatic exposure measured by gamma scintigraphy in Mrp2-deficient TR − rats compared to WT rats, suggesting that Mrp2 is involved in canalicular transport (4) . Furthermore, case reports have documented a failure to visualize the hepatobiliary tree after administration of 99m Tc-disofenin (DISIDA), the diisopropyl analogue of acetanilidoiminodiacetic acid, when administered to patients with Dubin-Johnson syndrome (MRP2-deficiency) (5). More than 98% of a 99m Tc-MEB dose is taken up by the liver; the hepatic excretion half-life of 99m Tc-MEB is rapid (16 min), and ∼1.5% of the dose was recovered in urine after 24 h in humans (2) .
99m Tc-MIBI, a monovalent cation complex of 99m Tc ( 99m Tc-2-methoxyisobutylisonitrile), is used clinically to assess myocardial perfusion; 99m Tc-MIBI distributes into the heart in proportion to blood flow and myocardial viability (6, 7) . Decreased uptake of 99m Tc-MIBI in resistant cells also has been attributed to a lower membrane potential and reduced mitochondrial density (8) . Several groups have used 99m Tc-MIBI as a functional P-gp probe substrate in rodents and humans (9) (10) (11) (12) . Further investigations using cancer cells in culture revealed that 99m Tc-MIBI is a MRP1 substrate (13) . In TR − rats, 99m Tc-MIBI cumulative recovery in bile, and liver activity profiles based on in vivo imaging, were similar compared to WT rats, suggesting that Mrp2 is not involved, or other mechanisms compensate for impaired hepatic excretion (14) . In humans, 99m Tc-MIBI undergoes renal elimination and fecal clearance mediated by biliary excretion and possibly intestinal secretion (Cardiolite ® package insert; (3)). 99m Tc-MIBI and analogs of 99m Tc-MEB have been used as probe substrates to assess interindividual variation in hepatic drug disposition (10, 15, 16) . Coadministration of 99m Tc-MIBI with the P-gp inhibitors PSC833 and LY335979 resulted in prolonged hepatic exposure (9, 11, 12) .
99m Tc-MIBI pharmacokinetics were altered in a cohort of cancer patients with common single nucleotide polymorphisms (SNPs) in ABCB1 exons 12 (C1236T) and 26 (C3435T); the elimination rate constant was significantly decreased (10) . However, the mechanisms of 99m Tc-MIBI hepatic transport have not been investigated fully, including potential compensatory proteins involved in hepatobiliary disposition. The purpose of the current study was to characterize the mechanisms of 99m Tc-MEB and 99m Tc-MIBI uptake and excretion in rat and human hepatocytes. The processes involved in hepatic uptake, basolateral efflux and canalicular excretion are too complicated to be completely elucidated in vivo. Therefore, suspended hepatocytes were used to investigate hepatic uptake mechanisms, and sandwich-cultured hepatocytes (SCH) were used to elucidate the hepatic efflux of 99m Tc-MEB and 99m Tc-MIBI. TR − rats serve as a useful tool to examine altered hepatobiliary disposition in response to impaired Mrp2 function and to facilitate the identification of compensatory basolateral and apical efflux mechanisms involved in 99m Tc-MEB hepatobiliary disposition.
MATERIAL AND METHODS

Materials
Dulbecco's modified Eagle's medium (DMEM), insulin, MEM non-essential amino acids solution (100x), L-glutamine, insulin and penicillin G-streptomycin solution were purchased from Invitrogen (Carlsbad, CA). Estradiol-17-β-D-glucuronide (E217G), para-aminohippuric acid sodium salt (PAH), tetraethylammonium (TEA), rifamycin SV, glycyrrhizic acid, clonidine, desipramine, ketoprofen, fetal bovine serum (FBS), Triton X-100, dexamethasone, and Hanks' balanced salt solution (HBSS) 
Suspended Hepatocyte Isolation/Uptake Studies
Rat hepatocytes were isolated by a two-step collagenase perfusion method as described previously (17) . Viability, as determined by trypan blue exclusion, was 90 to 95% (mean=92%). CellzDirect, Life Technologies (RTP, NC) kindly provided freshly isolated human hepatocytes in suspension. Hepatocyte donors included a 60-year-old female Caucasian and 63-and 69-year-old male Caucasians, with no recent history of smoking or alcohol use. Hepatocyte viability, as determined by trypan blue exclusion, was 90, 86 and 89%, respectively. Isolated hepatocytes were suspended at 1×10 6 cells/ml in cold modified Hank's buffer with 10 mM Tris/5 mM glucose (pH=7.4) or Na + -free choline buffer (10 mM Tris, 5 mM glucose, 5.4 mM KCl, 1.8 mM CaCl 2 , 0.9 mM MgSO 4 , 10 mM HEPES and 137 mM choline; pH=7.4) and stored on ice prior to conducting uptake studies (18) . Hepatocyte suspensions were preincubated in bottominverted Erlenmeyer flasks (rat) or 16×100 mm glass vials (human) at 37°C for 5 min; 0.1% DMSO or chemical inhibitor was added 1 min before, followed by 99m Tc-MEB (5 μCi/mL), 99m Tc-MIBI (5 μCi/mL), 3 H-E217G (1 μM, 60nCi/mL), 14 C-TEA (20 μM, 60nCi/mL) or 3 H-PAH (0.2, 1 or 20 μM, 60nCi/mL). The following concentrations of inhibitors were selected based upon reported affinities for the given active transport processes: 20 μM rifamycin SV (Oatp1a1, Oatp1a4, OATP1B1, OATP1B3, and OATP2B1 inhibitor), 20 μM glycyrrhizic acid (Oatp1a1, 1a4 and 1b2 inhibitor), 200 μM clonidine (organic cation transporter (Oct1) inhibitor), 10 μM desipramine (Oct1 and 3 inhibitor), 5 μM decynium 22 (OCT inhibitor), 10 μM ketoprofen (organic anion transporter (Oat2) inhibitor). Aliquots (100 μL) of the suspension were removed at timed intervals (up to 5 min), placed in 0.4-ml polyethylene tubes and centrifuged immediately through a top layer of silicone oil:mineral oil (82:18, v/v; 100 μL) and a bottom layer of 3 M KOH (50 μL).
99m Tc-MEB and 99m Tc-MIBI in the cell pellet and supernatant were analyzed using a sodium iodide well counter and corrected for decay ( 99m Tc t 1/2 =6.01 h). 3 H-E217G, 14 C-TEA or 3 H-PAH were analyzed by liquid scintillation counting. Adherent fluid volume was estimated with 14 C-inulin as described previously (19) . Protein concentrations for individual hepatocyte suspensions were determined with the BCA protein assay reagent kit (Pierce) as instructed by the manufacturer. BSA, as supplied by the manufacturer, was used as a standard (0.2-1 mg/mL).
Sandwich-Cultured Hepatocyte Studies
CellzDirect, Life Technologies (RTP, NC) provided human hepatocytes plated on six-well Biocoat™ plates and overlaid with Matrigel™. Hepatocyte donors were a 56-and 64-yearold female Caucasians with no history of smoking or alcohol use. Rat hepatocytes (>88% viability) were seeded (∼1.5× cells/well (WT)) in 6-well BioCoat™ plates and overlaid with Matrigel™ basement membrane matrix as described previously (20) . The culture medium was changed every 24 h until experiments were performed on day 4 of culture.
Efflux Studies
On day 4, efflux experiments were performed as previously described (21) with modifications. Briefly, hepatocytes were rinsed with 2 mL warm standard buffer and incubated with 1.5 mL of 99m Tc-MEB or 99m Tc-MIBI (5 μCi/ml) in standard HBSS for 20 min in a humidified incubator (95% O 2 , 5% CO 2 ) at 37°C. Subsequently, hepatocytes were rinsed vigorously twice with 2 mL warm standard HBSS or Ca Tc-MIBI in the efflux buffer was sampled at 20 min, and medium was aspirated. Hepatocytes were lysed as detailed above. Data were normalized to protein concentration in each well, as described above. Samples were analyzed using a gamma counter and corrected for decay.
The amount of substrate was measured in the medium at 20 min and in the lysed SCH at the end of the efflux phase. The extent of basolateral and canalicular efflux was determined based on the following equations and normalized to the total substrate mass preloaded in the hepatocytes, which was determined as the sum of the substrate mass in the efflux medium and in the hepatocyte lysate at the end of the efflux phase: 
Accumulation Studies
The method to determine substrate accumulation in the bile canalicular networks of SCH has been described previously (20, 21) . Cells were incubated for 10 min at 37°C with 1.5 mL of 99m Tc-MIBI (0.5 μCi/ml) with or without Bcrp knockdown, and in the presence and absence of 2 μM GF120918 in standard buffer. Substrate uptake was corrected for nonspecific binding by subtracting uptake on blank sixwell Biocoat™ plates overlaid with Matrigel™. Hepatocytes were lysed as detailed above, and data were normalized to protein concentration in each well, as described above.
The biliary excretion index (BEI,%) was calculated using B-CLEAR ® technology (Qualyst, Inc., Raleigh, NC; (21) where AUC 0-T represents the product of the incubation time (T) and the initial concentration in the medium. In vitro
Cl biliary values were scaled per kilogram body weight assuming the following: 200 mg protein/g rat liver tissue and 40 g rat liver tissue/kg body weight (22) .
RNA Interference (RNAi) Knockdown of Bcrp
The methods for packaging of recombinant siRNAexpressing adenoviral vectors and infection of SCH have been described previously (23) . Briefly, after seeding hepatocytes on Biocoat™ plates and changing seeding medium, cells were infected overnight with adenoviral vectors expressing non-target siRNA (siNT), or siRNA targeting the rat Bcrp gene at positions 288-306 (siBcrp) at a multiplicity of infection of 20. Cells were overlaid 24 h after seeding and cultured as described above. Bcrp knockdown was confirmed by Western blot analysis, and the in vitro Cl biliary of nitrofurantoin was determined using LC/MS/MS analysis, as detailed previously (23) .
Statistical Analysis
Statistically significant differences in the efflux data in rat SCH were determined by a two-way analysis of variance for the factors of treatment and route of efflux, which exhibited a significant interaction. Therefore, a one-way ANOVA was performed on basolateral and canalicular efflux data individually for the factor of treatment with Dunnett's post hoc test. A one-way ANOVA was performed on the initial uptake data in suspended hepatocytes with Dunnett's multiple comparisons post hoc test. The criterion for significance in all cases was p<0.05.
RESULTS
Uptake of 99m Tc-MEB, 99m Tc-MIBI, 3 H-E217G, and 14 
C-TEA in Suspended Rat and Human Hepatocytes
Preliminary experiments in suspended rat hepatocytes sampling over 60 min indicated that the linear range of uptake was 2.5, 1.5, 2.5, and 5 min for C-TEA, respectively. Therefore, subsequent experiments were conducted up to the respective times to evaluate the initial uptake rate of each substrate. The Oct/ OCT inhibitors clonidine, desipramine and decynium 22, and the Oat/OAT inhibitor ketoprofen, and the absence of sodium [substitution with choline-based buffer to rule out the involvement of sodium taurocholate cotransporter (Ntcp/ NTCP)] had marginal effects on the initial uptake of 99m Tc-MEB in WT rat and human hepatocytes compared to control (Fig. 1a and 2a) . Initial 99m Tc-MEB uptake was significantly reduced to 20.7 and 35.4% of control in the presence of the Oatp/OATP inhibitor rifamycin SV in WT rat and human hepatocytes, respectively (Fig. 1a and 2a) . In WT rat hepatocytes, the Oatp inhibitor glycyrrhizic acid significantly reduced 99m Tc-MEB initial uptake to 39.5% of control (Fig. 1a) . Initial Tc-MIBI uptake in suspended WT rat hepatocytes was not influenced by inhibitors or replacement of sodium with choline in the uptake buffer; all values were within 10% of control (Fig. 1b) .
In order to confirm the specificity of the selected inhibitors, transport of probe substrates was assessed in the presence of each inhibitor. As expected, initial hepatocyte uptake of the Oatp probe substrate 3 H-E217G was inhibited significantly to 15.5 and 23.8% of control in the presence of rifamycin SV and glycyrrhizic acid, respectively, in suspended WT rat hepatoyctes (Fig. 1c) , and 51.5% of control in the presence of rifamycin SV in suspended human hepatocytes (Fig. 2b) . All other inhibitors had marginal effects on 3 H-E217G uptake in both WT rat and human suspended hepatocytes (Fig. 1c and  2b) . Initial uptake of the Oct probe substrate 14 C-TEA was signficantly inhibited to 23.7% and 25.6% of control in the presence of clonidine and desipramine, respectively, in suspended rat hepatocytes (Fig. 1d) , and significantly reduced to 54.2% of control in the presence of decynium 22 (Fig. 2c) in suspended human hepatocytes. Interestingly, the Oatp1a1, Oatp1a4 and Oatp1b2 inhibitor glycyrrhizic acid signficantly reduced 14 C-TEA uptake by 62.1% compared to control in suspended rat hepatocytes (Fig. 1d) . The uptake of 20 μM 3 H-PAH over 60 min was marginally greater than background (data not shown), which was attributed primarily to nonspecific binding to the hepatocytes. 3 H-PAH uptake was not significantly influenced by the presence of 50 μM MK571 in the incubation medium (a known Mrp inhibitor added to inhibit potential basolateral efflux).
Hepatobiliary Disposition of
99m Tc-MEB in Rat and Human Sandwich-Cultured Hepatocytes 99m Tc-MEB canalicular efflux was slightly lower than basolateral efflux over 20 min in SCH from control WT rats (15.3±5.7% vs. 25.0±6.7% of total preloaded mass; Fig. 3a) . In contrast, in human SCH, 99m Tc-MEB canalicular efflux was greater than basolateral efflux (45.8 ±8.6% vs. 16.7±0.6% of total preloaded mass; Fig. 3a) . 99m Tc-MEB canalicular efflux was ∼3-fold greater in human compared to rat SCH, while basolateral efflux in human SCH was slightly lower than in rat SCH (Fig. 3a) . (Fig. 3a) . MK571 (100 μM) decreased 99m Tc-MEB canalicular efflux 85% in rat SCH and 30% in human SCH (Fig. 3a) , but increased 99m Tc-MEB basolateral efflux 136% in rat SCH and 240% in human SCH (Fig. 3a) .
99m Tc-MEB hepatocellular content (cell only) at the end of the 20-min efflux phase was slightly greater in rat SCH (58.7±7.3%) compared to human SCH (37.6±8.0%) (Table I) (Fig. 3b) .
99m Tc-MIBI canalicular efflux was similar between human and WT rat SCH, but basolateral efflux was 37% greater in human compared to WT rat SCH (Fig. 3b) .
99m Tc-MIBI basolateral efflux was similar in SCH from TR − and WT rats; likewise, canalicular efflux of 99m Tc-MIBI was not altered in SCH from TR − compared to WT rats (Fig. 3b) . GF120918 (20 μM) decreased 99m Tc-MIBI canalicular efflux 1.5-fold in rat SCH and 2.1-fold in human SCH. Interestingly, GF120918 also decreased 99m Tc-MIBI basolateral efflux in rat and human SCH (∼2.3-and ∼2.9-fold, respectively) (Fig. 3b) . Hepatocellular content of 99m Tc-MIBI at the end of the 20-min efflux phase tended to be greater in rat SCH compared to human SCH (Table I) , consistent with a greater percent of total efflux of 99m Tc-MIBI in human (89.4±1.8%) compared to rat (64.0±8.2%) SCH using the 20-min efflux study design.
Using the 10-min accumulation study design, 99m Tc-MIBI accumulation in cells + bile and cells was determined in rat SCH; BEI and in vitro Cl biliary values were 18% and 4.07 mL/min/kg, respectively. To examine whether Bcrp and/or P-gp were responsible for the biliary excretion of 99m Tc-MIBI in rat SCH, 10-min accumulation studies were conducted.
99m Tc-MIBI BEI (36.0 and 26.6%) and in vitro
Cl biliary (8.08 and 9.73 mL/min/kg) in day 4 WT rat SCH were increased marginally by infection with adenoviral vectors expressing a non-target control (siNT) or short hairpin RNA-targeting rat Bcrp (siBcrp), respectively, compared to noninfected SCH (Fig. 4a) . 99m Tc-MIBI BEI and in vitro Cl biliary were ablated in the presence of 2 μM GF120918 in siNT-and siBcrp-infected SCH, which resulted in a ∼2-fold increase in hepatocellular accumulation (cells only) of 99m Tc-MIBI (Fig. 4a) . As shown in Fig. 4b , in day 4 rat SCH, protein levels of Bcrp (normalized by β-actin) in siBcrp-infected cells were ∼20% of those in control (siNT-infected) cells. No differences in nitrofurantoin cellular accumulation, BEI, or in vitro Cl biliary in non-infected or control siNT-infected rat SCH were (Fig. 4c) . As expected, the cellular accumulation of nitrofurantoin, a Bcrp substrate, was increased due to the ∼6-fold decrease in BEI in siBcrp-infected cells compared to control (siNT-infected) cells.
DISCUSSION
The utility of 99m Tc-MEB and 99m Tc-MIBI as probe substrates for phenotyping the function of specific hepatic transport proteins was confirmed using well-established in vitro methods. Suspended hepatocytes and SCH were utilized from rats and humans to characterize hepatic uptake and efflux mechanisms in combination with the use of "specific" chemical inhibitors, as detailed in the methods, to examine the impact of hepatic transport modulation on the disposition of Tc-MIBI. Suspended hepatocytes are used primarily to investigate uptake mechanisms; the inability to differentiate between sinusoidal efflux and canalicular excretion limits the utility of suspended hepatocytes for efflux studies (24) (25) (26) . Isolation of hepatocytes by collagenase digestion and conventional cell culture results in the loss of many liver-specific functions, redistribution of canalicular membrane proteins, loss of cell polarity and architecture, including bile canaliculi, and the deterioration of hepatocyte viability within several days (27) (28) (29) . In contrast, hepatocytes cultured between two layers of gelled collagen (sandwich-cultured configuration) retain more in vivo-like properties, including formation of intact canalicular networks and polarized excretory function, and can be used to investigate the hepatobiliary disposition of substrates (21, (30) (31) (32) (33) (34) (35) .
Model probe substrates ( 3 H-E217G (36, 37), 14 C-TEA (38-40), and 3 H-PAH (41, 42)) were evaluated in the presence and absence of the panel of inhibitors to confirm the specificity of the selected inhibitors for Oatp/OATP (rifamycin SV and glycyrrhizic acid; Fig. 1c and 2b) , Oct/ OCT (clonidine, desipramine, and decynium 22; Fig. 1d and 2c) and Oat2/OAT2 (ketoprofen; data not shown), respectively. Unexpectedly, the Oatp/OATP inhibitor glyzyrrhizic acid significantly decreased 14 C-TEA initial uptake to 37.9% of control, suggesting that this inhibitor is not specific for Oatp isoforms because TEA is not a substrate of the Oatps expressed in the rat liver (43) . Surprisingly, incubation of freshly isolated rat and human hepatocytes with 0.2, 1 or 20 μM 3 H-PAH over 60 min in the absence and presence of 50 μM MK571, coadministered to inhibit potential basolateral efflux, resulted in no measurable increase in activity above background. Carrier-mediated retrieval of human OAT1 expressed in Xenopus oocytes and HEK293 cells from the cell membrane results in decreased function (44) . These findings suggest that Oat2/OAT2 may not be properly localized to assess transport function in freshly isolated rat and human hepatocytes.
Based on the specificity of the chosen inhibitors, 99m Tc-MEB and 99m Tc-MIBI hepatic uptake was examined.
99m Tc-MEB initial uptake was sodium-independent and was only affected by the Oatp/OATP inhibitors, rifamycin SV and glycyrrhizic acid (Fig. 1a and 2a) . These data support the hypothesis that 99m Tc-MEB uptake is predominantly mediated by Oatps/OATPs in rat and human hepatocytes and is in agreement with data demonstrating 99m Tc-MEB is a substrate of OATP1B1 and OATP1B3 in HEK293 overexpressing cells (3) .
99m Tc-MIBI initial uptake in rat hepatocytes was not influenced by inhibitors or the absence of sodium in the uptake buffer (Fig. 1b) , suggesting that an active transport process is not involved in Tc-MIBI uptake is a function of free diffusion based on electrical potentials across the plasma and mitochondrial membranes, with localization in the mitochondria by electrostatic forces (45) . Therefore, Tc-MIBI uptake experiments were not conducted in suspended human hepatocytes to conserve this limited resource.
Further studies were undertaken to examine the efflux processes involved in 99m Tc-MEB hepatic disposition. Remarkably, the canalicular efflux of 99m Tc-MEB was ∼3-fold greater in human compared to WT rat SCH, whereas the basolateral efflux was comparable (Fig. 3a) . Based on work by Li et al., total Mrp2/MRP2 protein was not significantly different in day 4 rat and day 7 human SCH (∼4fmol/μg protein), utilizing a quantitative LC-MS/MS analysis (46) . Thus, the species differences in canalilcular efflux of 99m Tc-MEB observed in the present study cannot be attributed to differences in the absolute amount of Mrp2/MRP2 protein primarily responsible for biliary excretion of 99m Tc-MEB, but could be explained by differences in affinity or maximum velocity, assuming that canalicular efflux is mediated solely by Mrp2/MRP2. 99m Tc-MEB total efflux also was greater in human compared to rat SCH due to this increased canalicular efflux (Fig. 3a) .
99m Tc-MEB canalicular efflux was completely ablated in TR − rat SCH. The Mrp2 inhibitor MK571 decreased 99m Tc-MEB canalicular efflux ∼6.7-fold in rat SCH, but only 30% in human SCH (Fig. 3a) . This apparent discrepancy could be due to a potential species difference in the hepatic disposition of MK571 leading to lower intracellular exposure of the inhibitor as a result of decreased uptake and/or increased clearance in human hepatocytes. Although species differences in the contribution of P-gp or BCRP to 99m Tc-MEB canalicular efflux in human compared to rat hepatocytes cannot be ruled out, the more likely explanation for these differences may be attributed to limitations in the experimental design of the efflux experiments. During the preloading phase, 99m Tc-MEB accumulates in the canalicular networks and may not be washed away completely before initiating the efflux phase; rapid canalicular excretion of 99m Tc-MEB may occur before MK571 had time to access the hepatocyte and reach the site of MRP2 inhibition, especially in human SCH. Overall, MK571 inhibition and the absence of 99m Tc-MEB in the bile canalicular networks of TR − rat SCH support the hypothesis that 99m Tc-MEB is a specific Mrp2 probe substrate, consistent with other reports documenting increased hepatic exposure of 99m Tc-MEB in TR − rats (4), and decreased biliary excretion in patients with Dubin-Johnson syndrome (MRP2-deficiency) administered 99m Tc-MEB analogs (5). 99m Tc-MEB basolateral efflux was increased in TR − rat SCH compared to WT, and in the presence of MK571 (Fig. 3a) , while intracellular accumulation of 99m Tc-MEB was unchanged (Table I) . These important findings suggest that this probe can be redirected from biliary excretion to efflux across the basolateral membrane. This increase in basolateral efflux also could be due, in part, to inhibition of 99m Tc-MEB hepatic re-uptake, because MK571 has been shown to inhibit OATP1B3 with a reported K i of 0.6 μM (47).
Further studies were conducted to investigate the efflux processes involved in 99m Tc-MIBI hepatic disposition. The absence of Mrp2 in TR − rat SCH did not alter basolateral or canalicular efflux, suggesting that either Mrp2 is not involved, or other proteins (e.g. P-gp) are able to fully compensate (Fig. 3b) . In TR − rats, 99m Tc-MIBI hepatic scintigraphy and biliary excretion were unchanged compared to WT control rats (14) .
99m Tc-MIBI efflux was assessed in the presence of 20 μM GF120918, a concentration 10-fold greater than previously used to inhibit P-gp in rat SCH (48) . This concentration was selected based on studies in cancer cell lines expressing multidrug resistance transport proteins (P-gp and Bcrp), demonstrating GF120918 is a more potent inhibitor of P-gp than Bcrp by an order of magnitude or more (49) , and the use of 10 μM GF120918 in isolated perfused rat livers to impair Bcrp-mediated biliary excretion of 4-methylumbelliferyl sulfate generated in the hepatocyte (50) . As expected, 99m Tc-MIBI canalicular efflux was GF120918-sensitive, consistent with a role for P-gp and/or Bcrp in 99m Tc-MIBI biliary excretion. Surprisingly, 99m Tc-MIBI basolateral efflux was GF120918-sensitive, suggesting involvement of an active transport process. Hepatocellular accumulation of 99m Tc-MIBI increased in the presence of 99m Tc-Labeled Hepatic Transport ProbesGF120918 (Table I) due to decreased basolateral and canalicular efflux of 99m Tc-MIBI (Fig. 3b) . In order to further investigate the transport processes involved in 99m Tc-MIBI biliary excretion, accumulation studies were conducted in rat SCH. The involvement of Bcrp in the biliary excretion of 99m Tc-MIBI was assessed with the use of RNAi knockdown of Bcrp, as confirmed by immunoblot (Fig. 4b) , and significantly impaired biliary excretion of the rat Bcrp probe substrate nitrofurantoin (Fig. 4c) . This approach using adenoviral vectors expressing a non-target control (siNT) and short hairpin RNA-targeting Bcrp (siBcrp) has been shown to efficiently and specifically knock down Bcrp in rat SCH (23) . Bcrp knockdown did not affect 99m Tc-MIBI cellular accumulation, biliary excretion or in vitro Cl biliary (Fig. 4a) . Tc-MIBI biliary excretion was inhibited completely by 2 μM GF120918 (Fig. 4a) , used previously to inhibit P-gp in rat SCH (48) . Cellular accumulation also increased in the presence of GF120918 (Fig. 4a ), suggesting that P-gp is the primary protein responsible for the biliary excretion of 99m Tc-MIBI. These findings are in agreement with published in vitro data demonstrating the affinity of 99m Tc-MIBI for P-gp in overexpressing cancer cell lines (51, 52) and with human in vivo data; 99m Tc-MIBI biliary elimination was reduced and/ or hepatic 99m Tc-MIBI retention was increased based on scintigraphy in humans with single nucleotide polymorphisms in the ABCB1 gene resulting in decreased P-gp function (10) , and in cancer patients administered 99m Tc-MIBI and the P-gp inhibitor PSC833 (9, 11). Species differences existed in the fraction of canalicular vs. basolateral efflux of 99m Tc-MEB in rat (38.0% vs. 62.0% of total efflux, respectively) compared to human (73.3% vs. 26.7% of total efflux, respectively; Fig. 3a ) SCH. These in vitro findings support the clinical observation that biliary clearance is rapid and extensive in humans; ∼84% of a 2.3 mCi dose of intravenously administered 99m Tc-MEB was recovered in bile in healthy human subjects within 180 min (53) . In rats, the biliary excretion profile of 99m Tc-MEB may be more prolonged due to basolateral efflux and subsequent reuptake by hepatocytes; ∼95% of a 0.25 mCi dose was recovered in the liver 30 min after intravenous administration (54) . In contrast, based on the fraction of canalicular vs. basolateral efflux of 99m Tc-MIBI in rat (36.8% vs. 63.2% of total efflux, respectively) and human (28.3% vs. 71.7% of total efflux, respectively; Fig. 3b ) SCH, basolateral excretion of Tc-MIBI appears to be the preferential route of hepatic elimination of this probe in both rats and humans. This finding is consistent with biliary recovery of only ∼22% of a 3.1 mCi dose of intravenously administered 99m Tc-MIBI in healthy human subjects (55) . Overall, the efflux method in SCH is useful for examining the preferential route of hepatic excretion (canalicular vs. basolateral) and elucidating species differences in hepatic efflux.
In summary, the hepatic uptake of 99m Tc-MIBI appears to occur by passive diffusion; 99m Tc-MIBI biliary excretion is mediated by P-gp.
99m Tc-MEB hepatic uptake is predominantly Oatp-mediated with biliary excretion by Mrp2. Species differences exist between rat and human in the total efflux and route of efflux for 99m Tc-MEB. Preloading SCH and measurement of efflux over 20 min in SCH is a useful approach to investigate the route of hepatic excretion (basolateral vs. canalicular), species differences in basolateral and canalicular efflux, and compensatory changes in canalicular and basolateral efflux due to impaired transport function associated with drug interactions, disease state alterations or genetic variation.
